• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Afro-Egyptian Journal of Infectious and Endemic Diseases
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 13 (2023)
Volume Volume 12 (2022)
Volume Volume 11 (2021)
Volume Volume 10 (2020)
Volume Volume 9 (2019)
Volume Volume 8 (2018)
Volume Volume 7 (2017)
Volume Volume 6 (2016)
Volume Volume 5 (2015)
Volume Volume 4 (2014)
Volume Volume 3 (2013)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 2 (2012)
Volume Volume 1 (2011)
Abo-Taleb, F., El-Hefeni, A., Kotb, A., El-Gohary, T. (2013). Efficacy of Ribavirin to Prevent Hepatitis Reactivation in Hepatitis C Virus-infected Patients Treated for Non-Hodgkin Lymphoma. Afro-Egyptian Journal of Infectious and Endemic Diseases, 3(1), 17-26. doi: 10.21608/aeji.2013.17092
Fouad M Abo-Taleb; Ashraf M El-Hefeni; Ahmed Kotb; Tarek A El-Gohary. "Efficacy of Ribavirin to Prevent Hepatitis Reactivation in Hepatitis C Virus-infected Patients Treated for Non-Hodgkin Lymphoma". Afro-Egyptian Journal of Infectious and Endemic Diseases, 3, 1, 2013, 17-26. doi: 10.21608/aeji.2013.17092
Abo-Taleb, F., El-Hefeni, A., Kotb, A., El-Gohary, T. (2013). 'Efficacy of Ribavirin to Prevent Hepatitis Reactivation in Hepatitis C Virus-infected Patients Treated for Non-Hodgkin Lymphoma', Afro-Egyptian Journal of Infectious and Endemic Diseases, 3(1), pp. 17-26. doi: 10.21608/aeji.2013.17092
Abo-Taleb, F., El-Hefeni, A., Kotb, A., El-Gohary, T. Efficacy of Ribavirin to Prevent Hepatitis Reactivation in Hepatitis C Virus-infected Patients Treated for Non-Hodgkin Lymphoma. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2013; 3(1): 17-26. doi: 10.21608/aeji.2013.17092

Efficacy of Ribavirin to Prevent Hepatitis Reactivation in Hepatitis C Virus-infected Patients Treated for Non-Hodgkin Lymphoma

Article 3, Volume 3, Issue 1, March 2013, Page 17-26  XML PDF (322.96 K)
Document Type: Original Article
DOI: 10.21608/aeji.2013.17092
Authors
Fouad M Abo-Taleb; Ashraf M El-Hefeni; Ahmed Kotb; Tarek A El-Gohary
Medical Oncology and Hematology Department, Faculty of Medicine, Zagazig University, Egypt
Abstract
Background and study aim:: Reports have found an association between B cell non-Hodgkin lymphomas (NHL) and Hepatitis C virus (HCV) infection. However, data on acute exacerbation and reactivation of chronic HCV infection following chemotherapy are very limited. We studied the efficacy of ribavirin to prevent hepatitis reactivation in HCV-infected patients treated for NHL.
Patients and methods: This study was carried out at Medical Oncology & Hematology  Department , Zagazig University Hospitals. It included 57 patients with  B-cell NHL who were naïve to chemotherapy,  among them 24 patients  were positive for HCV and 33 patients were negative for HCV (group C). The HCV positive group were subdivided into 11 patients who received ribavirin (group A) and 13 patients did not receive ribavirin (group B). Routine investigations for NHL were done, HCV RNA was measured for HCV positive patients before  and after the end of chemotherapy.
Results :HCV infection occurred in 42% of patients with B cell NHL. Acute hepatic enzyme exacerbation occurred in 8 (14%) of all patients with the highest percentage was 29.2 % among HCV infected patients (7/24), while only one patient (3%) in the HCV negative group (p= 0.007). Among the 24 NHL patients with  HCV positivity, we compared group A  versus group B during chemotherapy  as regards to  hepatic enzyme flare, it was ( 27% & 30%, respectively, p= 0.6). Five (20.8%) of 24 NHL patients with HCV positivity developed HCV PCR reactivation; 2 patients of group A and 3 patients of group B  (18.2% & 23.1%, respectively, p= 0.58). The outcome was comparable between the three groups.
Conclusion : The frequency of HCV infection in patients with B cell NHL is higher than in the general population. Acute exacerbation and reactivation of chronic HCV infection occur in a sizeable subset of patients with NHL during chemotherapy. The use of ribavirin did not decrease  hepatic enzyme flare or  HCV PCR reactivation during chemotherapy.
Keywords
Hepatitis C virus; Ribavirin; Non-Hodgkin lymphoma; Reactivation
Main Subjects
Hepatology
Statistics
Article View: 155
PDF Download: 284
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.